Swedish CELLINK AB buys the German biotech company Scienion AG for around 80 million €

The 2016 founded CELLINK AB agreed with the shareholders – including the NRW.Bank – to buy the Scienion AG for around 80 M €. The total purchase price is paid half with cash and half with newly issued CELLINK shares for 146.6 SEK per share. Translating to 2,814,032 shares corresponding to approximately 4.9% of the votes and approximately 6.5% of the share capital in CELLINK.

The biotech company Scienion with offices in Berlin and Dortmund was founded in 2001 as a spin-off of the Max-Planck-Institute of molecular genetics. Since then it has become a leading actor in the pico- and nanoliter dispensing technology. According to CELLINK the companies’ synergies enable greater market opportunities for CELLINK’s and Scienion’s product portfolio. Also, does CELLINK highlights the preliminary, good numbers of Sciencion with 21.5 M € revenue and an EBITDA margin of 23.6% in 2019.
Scienion will remain under the current entity and management post-transaction
Further information can be found here